We are hereby submitting the Newspaper Advertisement in Hitech Edition (English Language) and Prajapalana (Telugu Language) regarding Unaudited Standalone financial results for the Third ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hindustan Bio Sciences Ltd has submitted to BSE the newspaper clippings of its unaudited standalone financial results for the quarter ended December 31, 2025, published on February 1, 2026 in Hitech (English) and Prajapalana (Telugu). This is a routine compliance filing under SEBI LODR Regulation 47. From the published results, revenue from operations stood at Rs 38.25 lakhs in Q3 FY26, down from Rs 70.44 lakhs in Q3 FY25. Despite the revenue dip, the company swung to a net profit of Rs 8.20 lakhs versus a loss of Rs 5.85 lakhs in the year-ago quarter. For the nine months ended December 2025, net profit came in at Rs 3.74 lakhs, improving from a loss of Rs 0.98 lakhs in 9M FY25. EPS for Q3 FY26 was Rs 0.08 per share (basic).
No new material event — this is just the statutory newspaper publication of results already reported. The numbers show shrinking top-line revenue but improved bottom-line profitability year-on-year; investors should track whether revenue stabilises in coming quarters.